Sponsored, no-charge genetic testing brought to you by Invitae and Decibel Therapeutics, for children diagnosed with auditory neuropathy.

  • UNITED STATES

  • AUSTRALIA

Genetic testing for auditory neuropathy may bring a patient one step closer to diagnosis and appropriate clinical management:

  • Approximately 10% of children who are born with hearing loss have test results consistent with auditory neuropathy.
  • Auditory neuropathy is a hearing disorder in which the hearing organ located in the inner ear receives sound normally; however, the transmission of this sound to the brain is interrupted.
  • There are several genetic causes of auditory neuropathy. The most common genetic cause results in insufficient production of a protein called otoferlin. 
  • The otoferlin protein enables communication between the inner ear sensory cells and the auditory nerve. When this protein is deficient, the ear cannot communicate with the nerve and brain. This results in severe to profound hearing loss.

About the Amplify™ genetic testing program

Program eligibility

This program is available to individuals with all the following:
  • Absent or Highly Abnormal Auditory Brainstem Response (ABR) in both ears.
  • Presence of Distortion Product Otoacoustic Emissions (DPOAE) in at least 3 frequencies in at least one ear.
  • Less than 5 years of age.

Genetic testing with Invitae

The Amplify™ program offers testing with the Invitae Comprehensive Deafness Panel, which analyzes genes associated with syndromic and non-syndromic deafness. Broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication.

VIEW PANEL

How to order (US)

1. Submit an order

To place your online order, click here and follow the on-screen prompts.

To place a paper-based order, download the paper order form and include it in the specimen box. 

2. Collect a specimen

If a specimen collection kit was not ordered during the online ordering workflow, order a blood, buccal, or saliva collection kit here
Please view specimen and shipping requirements for important information, and be sure to include the completed requisition form in the kit with the specimen. 

3. Receive results

On average, results are available 10-21 days after Invitae receives the specimen. You will receive a notification email once the test results are ready.
Log in to view the status of your online order. 

Next steps and additional services 

​​​​​​

Family variant testing for familial insights

If a positive result is identified, testing for your patient’s family members is available.

Simply follow the ordering instructions, selecting only the gene(s) you are interested in testing for the family member. The partner code will automatically be added with the order.

LEARN MORE

Regional-specific program materials:

United States:
Test Requisition Form (US)
Informed Patient Consent (English - US only)
Program Flyer (English)

Australia:
Test Requisition Form (Australia)
Informed Patient Consent (English -  Outside US)
Program Flyer (English)

*To order a test kit in Australia, please send an email to apac@invitae.com with the requested kit type (saliva, blood, buccal), number of kits requested, sponsored testing program name, clinician name, email, phone number and address. If you're interested in shipping a saliva kit directly to a patient, please specify that in your email and include the patient's name and address.

Support every step of the way

Client Services

Available to answer your questions or help you through the testing process.

Clinical Support Services

Licensed, board-certified genetic counselors, ready to support you.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website.


About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company focused on developing treatments that restore functional hair cells within the inner ear to treat disorders of hearing and balance. Leveraging industry-leading single-cell genomics capabilities and proprietary gene therapy technologies, Decibel has established a comprehensive research, discovery and drug development platform aimed at restoring hearing and balance function. Decibel’s pipeline, including its lead gene therapy program (DB-OTO) to treat congenital monogenic deafness and its ototoxicity prevention program, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow @DecibelTx.